These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19721197)

  • 41. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonists.
    Hastings KL
    Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):489-92. PubMed ID: 16859399
    [No Abstract]   [Full Text] [Related]  

  • 43. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of thiazolidinediones on BMD and osteoporosis.
    McDonough AK; Rosenthal RS; Cao X; Saag KG
    Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):507-13. PubMed ID: 18695700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors.
    Fang F; Kang Z; Wong C
    Mol Nutr Food Res; 2010 Mar; 54(3):345-52. PubMed ID: 19866471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
    Grey A; Bolland M; Gamble G; Wattie D; Horne A; Davidson J; Reid IR
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1305-10. PubMed ID: 17264176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
    Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
    J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.
    Yamagishi S; Ogasawara S; Mizukami H; Yajima N; Wada R; Sugawara A; Yagihashi S
    J Neurochem; 2008 Jan; 104(2):491-9. PubMed ID: 17995925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
    Gupta M; Mahajan VK; Mehta KS; Chauhan PS; Rawat R
    Arch Dermatol Res; 2015 Nov; 307(9):767-80. PubMed ID: 25986745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone loss and fracture risk associated with thiazolidinedione therapy.
    Riche DM; King ST
    Pharmacotherapy; 2010 Jul; 30(7):716-27. PubMed ID: 20575635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [PPAR family and its relationship to metabolic syndrome].
    Zhang XY; Chen LH; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [PPARs: the role in glucose and lipid homeostasis, insulin resistance and atherosclerosis].
    Hrebícek J
    Cesk Fysiol; 2004; 53(1):4-16. PubMed ID: 15702884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PPARs: diverse regulators in energy metabolism and metabolic diseases.
    Wang YX
    Cell Res; 2010 Feb; 20(2):124-37. PubMed ID: 20101262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetes and skeletal health.
    Yaturu S
    J Diabetes; 2009 Dec; 1(4):246-54. PubMed ID: 20923525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.
    Eldor R; DeFronzo RA; Abdul-Ghani M
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S162-74. PubMed ID: 23882042
    [No Abstract]   [Full Text] [Related]  

  • 60. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
    Gaikwad AB; Viswanad B; Ramarao P
    Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.